Recent Advances in Anticancer Strategies
Cancers,
Journal Year:
2025,
Volume and Issue:
17(2), P. 173 - 173
Published: Jan. 8, 2025
Due
to
the
intricate
nature
of
cancer
development
and
progression,
various
types
are
increasingly
prevalent
worldwide
[...].
Language: Английский
Epigenetic drugs in cancer therapy
Cancer and Metastasis Reviews,
Journal Year:
2025,
Volume and Issue:
44(1)
Published: Feb. 26, 2025
Abstract
Genetic
and
epigenetic
modifications
of
DNA
are
involved
in
cancer
initiation
progression.
Epigenetic
change
chromatin
structure
accessibility
thus
affect
replication,
repair
transcription.
reversible
include
methylation,
histone
acetylation
methylation.
methylation
is
catalysed
by
methyltransferases,
deacetylation
acetylases
deacetylases,
while
methyltransferases.
dysregulated
several
cancers,
making
them
therapeutic
targets.
drugs
(epi-drugs)
which
inhibitors
methyltransferase
(DNMTi),
deacetylase
(HDACi),
(HMTi)
bromodomain
extra-terminal
motif
protein
(BETi),
have
demonstrated
clinical
success
as
anti-cancer
agents.
Furthermore,
the
combination
epi-drugs
with
standard
chemotherapeutic
agents
has
promising
effects
pre-clinical
settings.
In
this
review,
we
discuss
role
therapy
explore
their
current
future
use
other
used
clinic.
We
further
highlight
side
limitations
epi-drugs.
additionally
novel
delivery
methods
tumour
biomarkers
for
screening,
diagnosis
development
personalised
treatments,
order
to
reduce
off-target
toxicity
improve
specificity
anti-tumour
efficacy
Language: Английский
Epigenetic Modifications as Novel Biomarkers for Diagnosis, Prognosis, and Therapeutic Targeting in Thyroid, Pancreas, and Lung Neuroendocrine Tumors
Federica Colapietra,
No information about this author
Paola Della Monica,
No information about this author
Raffaella Di Napoli
No information about this author
et al.
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(8), P. 2622 - 2622
Published: April 11, 2025
Neuroendocrine
neoplasms
(NENs)
comprise
a
heterogeneous
tumor
group
arising
from
neuroendocrine
cells,
commonly
originating
in
the
gastroenteropancreatic
tract
and
bronchopulmonary
system.
Their
incidence
has
risen
significantly,
owing
to
improved
diagnostic
techniques
increased
clinical
recognition.
While
previous
reviews
have
explored
molecular
genetic
basis
of
NENs,
limited
attention
been
given
role
epigenetic
modifications,
particularly
DNA
methylation,
tumorigenesis
disease
progression.
This
review
focuses
on
lung,
pancreas,
thyroid
well-differentiated
tumors
(NETs),
highlighting
mechanisms,
as
promising
biomarkers
for
early
diagnosis
risk
stratification.
Aberrant
methylation
can
silence
key
suppressor
genes,
including
RASSF1A
CDKN2A,
thereby
promoting
tumorigenesis.
Integrating
profiles
with
conventional
such
chromogranin
A
(CgA)
may
enhance
accuracy
inform
therapeutic
strategies.
Emerging
therapies
offer
potential
avenues
personalized
treatment
based
profiling.
Unlike
prior
that
broadly
cover
changes
this
uniquely
emphasizes
translational
practice.
By
synthesizing
recent
findings
evaluating
their
implications,
we
aim
bridge
gap
between
research
practical
applications
diagnosis,
prognosis,
therapy.
Language: Английский
Characterization of N6-methyladenosine long non-coding RNAs in sporadic congenital cataract and age-related cataract
International Journal of Ophthalmology,
Journal Year:
2024,
Volume and Issue:
17(11), P. 1973 - 1986
Published: Oct. 23, 2024
AIM:
To
characterize
the
N6-methyladenosine
(m6A)
modification
patterns
in
long
non-coding
RNAs
(lncRNAs)
sporadic
congenital
cataract
(CC)
and
age-related
(ARC).
METHODS:
Anterior
capsule
of
lens
were
collected
from
patients
with
CC
ARC.
Methylated
RNA
immunoprecipitation
next-generation
sequencing
performed
to
identify
m6A-tagged
lncRNAs
expression.
Kyoto
Encyclopedia
Genes
Genomes
pathway
enrichment
analyses
Gene
Ontology
annotation
used
predict
potential
functions
m6A-lncRNAs.
RESULTS:
Large
amount
m6A
peaks
within
lncRNA
identified
for
both
ARC,
while
level
was
much
higher
ARC
(49
870
peaks)
than
that
(18
688
peaks),
yet
those
difference
between
younger
age
group
(ARC-1)
elder
(ARC-2)
quite
slight.
A
total
1305
hypermethylated
1178
hypomethylated
lncRNAs,
as
well
182
differential
expressed
exhibited
compared
CC.
On
other
hand,
5893
5213
155
significantly
altered
ARC-2
ARC-1.
Altered
mainly
associated
organization
biogenesis
intracellular
organelles,
nucleotide
excision
repair.
CONCLUSION:
Our
results
first
time
present
an
overview
methylomes
providing
a
solid
basis
uncovering
new
insight
reveal
pathogenic
mechanism
Language: Английский
Diagnostics and Therapy for Malignant Tumors
Chih‐Yang Tsai,
No information about this author
Chunyu Wang,
No information about this author
Hasok Chang
No information about this author
et al.
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(12), P. 2659 - 2659
Published: Nov. 21, 2024
Malignant
tumors
remain
one
of
the
most
significant
global
health
challenges
and
contribute
to
high
mortality
rates
across
various
cancer
types.
The
complex
nature
these
requires
multifaceted
diagnostic
therapeutic
approaches.
This
review
explores
current
advancements
in
methods,
including
molecular
imaging,
biomarkers,
liquid
biopsies.
It
also
delves
into
evolution
strategies,
surgery,
chemotherapy,
radiation
therapy,
novel
targeted
therapies
such
as
immunotherapy
gene
therapy.
Although
progress
has
been
made
understanding
biology,
future
oncology
lies
integration
precision
medicine,
improved
tools,
personalized
approaches
that
address
tumor
heterogeneity.
aims
provide
a
comprehensive
overview
state
diagnostics
treatments
while
highlighting
emerging
trends
lie
ahead.
Language: Английский